Stripe funds $500M Intercept to target colds and flu, aiming at all respiratory viruses

Stripe is putting $500 million behind a new nonprofit, Intercept, with a very ambitious target: preventing both the common cold and the flu, and eventually getting rid of respiratory viruses altogether. The effort is backed not just by Stripe, but also by Anthropic, the OpenAI Foundation, Flu Lab, and additional funders including Bill Gates and traders at Jane Street Capital, according to an Intercept spokesperson.

The near-term plan is a portfolio approach: Intercept will use grants and investments to back prevention approaches that include vaccines and “large-scale air-cleaning systems for schools, offices, and other public spaces.” In plain English, the bet is that vaccines and medical countermeasures might not be enough on their own, so the group is also looking at removing viruses from the air in shared environments. The headline stakes are clear: this is a serious attempt to treat respiratory infections as something closer to a systems problem, not a recurring nuisance.

Why now, and why here? Ransohoff, the Stripe executive leading the initiative along with Charlie Petty, a venture capitalist who joined Stripe this year, says the problem has been underweighted. She compares respiratory infections to a minor nuisance while also pointing to the burden they impose on society, and she cites a figure that the average person will spend 5% of their lifetime fighting a cold or the flu. That statistic is less about comfort and more about opportunity cost: time off work, healthcare strain, and the broad drag that happens when illness cycles through schools, offices, and families.

The uncomfortable scientific reason this has been hard is also baked into the model. The common cold is caused by more than 200 different viruses, according to the American Lung Association, with rhinoviruses being the most common. With that level of diversity, traditional vaccine logic runs into a wall. Intercept’s stance aligns with Ransohoff’s explanation that it typically doesn’t pay to try to stop any one virus with a vaccine, and that, historically, pharma companies have not viewed colds as attractive compared to other targets because of the incentive mismatch. In other words, the market has treated prevention as low ROI, even if the lived cost of getting sick is enormous.

Intercept’s strategy tries to sidestep the “one virus, one product” trap by leaning into broader countermeasures that can work against many viruses at once. The concept took shape after Ransohoff started talking with David Veesler, a structural biologist and vaccine designer at the University of Washington, who argued that it’s possible to build broad countermeasures. Ransohoff describes Veesler as “nerd-sniping” her, convincing her that the approach is technically possible while also helping clarify that a big reason this has not been done is an incentive problem. This framing matters for boards and investors because it turns “why hasn’t anyone fixed this?” into “what would capital do if it targeted the right bottleneck?”

Veesler points to a growing scientific toolkit that has changed what’s possible, including RNA drugs, antibodies, and computational protein design. One idea the group is exploring is engineering virus-grabbing proteins that people could spray in their nasal passages to catch viruses before they can infect. Veesler also connects the timing to the lessons of covid-19, saying his group was among those involved in rapid development of vaccines, anti-viral drugs, and antibodies. Intercept is effectively trying to import that speed and technology readiness into respiratory prevention more generally, rather than waiting for a single respiratory pathogen to dominate headlines.

If you zoom out, Intercept’s air-cleaning component reflects a regulatory and operational logic: public spaces are where viral transmission accelerates, and physical mitigation can be scaled. Intercept says its interest includes using strong ultraviolet light to inactivate viruses. The group compares the concept to how municipalities remove impurities from water supply before it is piped to homes, aiming to remove viruses from the air the same way. That analogy is more than a metaphor. It suggests an institutional buyer and a repeatable deployment path, particularly for schools and offices, not just a pharmaceutical rollout.

There is also a clear backdrop in the funding landscape. The US funds about $6.5 billion a year in virus research through the National Institute of Allergy and Infectious Disease (NIAID), but that agency’s budget has not grown in recent years, according to the source, leaving more room for private philanthropy. Stripe’s philanthropic track record also matters here because it signals comfort with long cycles and technical uncertainty. The Collison brothers previously organized a $1.8 billion program called Frontier to encourage development of carbon removal technology. Ransohoff draws a parallel between removing carbon from the atmosphere and getting rid of respiratory viruses: both are “technically possible” but lack commercial incentives. More specifically for biology, she notes that after “fast grants” during the covid-19 pandemic, the Collison brothers later joined other donors who committed $650 million to establish the Arc Institute in Palo Alto, which has developed AI models for biological research.

Intercept’s advisers include Peter Marks, a former top FDA official, and Moncef Slaoui, the pharmaceutical executive who led the US coronavirus vaccine effort, Operation Warp Speed. That matters because it links the initiative to real-world regulatory and development pathways, potentially helping teams navigate the translate-from-lab-to-clinic gap. The strategic challenge the organization faces is obvious and acknowledged: figuring out how to counter many, even all, viruses at one time. The effort is essentially a bet that prevention can be treated like an engineering problem, not just a drug pipeline problem.

For executives in biotech, public health, and adjacent industries, the second-order implication is hard to ignore. This is a $500 million attempt to change the incentives around respiratory infections by funding both biology and deployment infrastructure, and by attacking the “diversity is too daunting, so people don’t even try” logic. If Intercept works even partially, it may reset expectations for what private capital should back in prevention, and what regulators and institutions might be willing to support when the goal is not just treatment, but reducing the baseline burden of illness across communities.